74286-87-6

Usage

Uses

Used in Organic Synthesis:
8-(BromoMethyl)-1,4-dioxaspiro[4.5]decane is used as a reagent for the formation of new carbon-carbon and carbon-heteroatom bonds due to its reactive bromomethyl group, which can engage in various reactions with nucleophiles.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 8-(BromoMethyl)-1,4-dioxaspiro[4.5]decane is utilized as a key intermediate in the synthesis of potential drug candidates. Its unique properties and reactivity contribute to the development of biologically active compounds, underscoring its significance in medicinal chemistry.
Used in the Design and Development of Biologically Active Compounds:
8-(BromoMethyl)-1,4-dioxaspiro[4.5]decane is employed as a structural component in the creation of biologically active molecules, leveraging its spirocyclic framework to enhance the compound's properties and effectiveness in various therapeutic applications.

Upstream product

• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 26845-47-6 methyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 

Downstream Products

• 197387-33-0 4-(bromomethyl)cyclohexanone 
• 352231-38-0 1-(1.4-Dioxaspiro[4.5]dec-8-ylmethyl)-3-(2-methoxyphenyl)pyrrolidine 
• 74302-79-7 4-(phenylthiomethyl)cyclohexanone 
• 74302-78-6 8-(phenylthiomethyl)-1,4-dioxaspiro<4,5>decane 

Relevant academic research and scientific papers

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

1-METHYL-4-[(4-PHENYLPHENYL)SULFONYLMETHYL]CYCLOHEXYANOL AND 1-METHYL-4-[[4-(2-PYRIDYL)PHENYL]SULFONYLMETHYL]CYCLOHEXANOL COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylme

Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11β-HSD1 inhibitors

Discovery and optimization of a piperidyl benzamide series of 11β-HSD1 inhibitors is described. This series was derived from a cyclohexyl benzamide lead structures to address PXR selectivity, high non-specific protein binding, poor solubility, limited in

Sulphur participation in cyclization reactions

Cyclization initiated by thiiranium ions was investigated.Cis-fused decalins were formed by a process involving inversion.In nitromethane a sulphonium salt 8 was formed.The reactions of 8 with nucleophilic reagent deviated from those of comparable compoun